Abstract
Overview
Introduction
Datamonitor expects the antihypertensives market to reach $37 billion, across the seven major markets, by 2017. The growth will be driven by the uptake of Novartis' s Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizer' s Norvasc and Merck' s Cozaar, will restrain market growth.
Scope
- Description of the competitive landscape in antihypertensives across seven major markets with market definition and overview.
- Definition of the unmet needs in the antihypertensives market.
- Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.
- Analysis of major events and brand dynamics affecting the hypertension market.
Highlights
The growth rate of the antihypertensive market is declining. The market is mature and does not present an attractive opportunity for R&D expenditure; consequently Big Pharma are shying away from the pursuit of novel mechanisms of action in favour of developing more efficacious combination therapies.
Cozaar' s and Diovan' s patent expiries in the US have the potential to alter the structure of the antihypertensive market dramatically. Threats of generic substitution and money-saving healthcare strategies which have plagued other markets, are now approaching the successful ARB class, and will have an impact on the whole antihypertensive market.
Novartis is set to strengthen its position in the antihypertensives arena; Tekturna is expected to achieve moderate sales and together with Exforge form a potential for market expansion. This however will be set back by the premature expiry of Pfizer' s Norvasc patent.
Reasons to Purchase
- Quantify the future size of the antihypertensives market and identify opportunities for new products.
- Learn how recent changes related to product expiries will shape the antihypertensives market.
- Understand the barriers to uptake for novel antihypertensive agents, and the need for paradigm shift in clinical trial design.
Table of Contents
- ABOUT DATAMONITOR HEALTHCARE
- About the cardiovascular pharmaceutical analysis team
- CHAPTER 1 EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the disease market
- Related reports
- CHAPTER 2 MARKET DEFINITION AND OVERVIEW
- Definition of drug classes
- Current seven major market assessment
- The antihypertensives market segmented by class
- The antihypertensives market segmented by country
- Antihypertensive market landscape
- Historical influences on the market
- Strategic scope
- Consideration of market unmet needs
- Conflicting evidence from clinical trials and guideline alterations
- Paradigm shift in antihypertensive R&D
- Defining the unmet need in the antihypertensives market
- Beyond blood pressure reduction
- Improved diagnosis
- Improved blood pressure management
- Increased uptake of fixed-dose combination therapies
- Targeting global cardiovascular risk and organ damage
- Patient and primary care physician education
- Rest of World snapshot
- Current market assessment
- Future seven major market assessment
- Overview
- Market drivers and market restraints
- Key factors driving growth of the antihypertensives market
- Factors restraining growth of the antihypertensives market
- Forecast summary
- Key events summary
- CHAPTER 3 BRAND DYNAMICS
- Overview of the competitive landscape
- Angiotensin receptor blockers
- Class level events
- Blopress/Atacand (candesartan)
- Diovan/Co-Diovan (valsartan/valsartan + HCTZ)
- Exforge (valsartan+ amlodipine)
- Cozaar (losartan)/Hyzaar (losartan + HTCZ)
- Micardis (telmisartan)
- Benicar (olmesartan)
- Angiotensin converting enzyme inhibitors
- Lotrel (amlodipine + benazepril)
- Beta blockers
- Betaloc (metoprolol)
- Kredex (carvedilol)
- Calcium channel blockers
- Norvasc (amlodipine)
- Diuretics
- Renin inhibitors
- Tekturna/Rasilez (aliskiren)
- BIBLIOGRAPHY
- Journal papers
- Websites
- Datamonitor reports
- APPENDIX A: MARKET ASSUMPTIONS
- New product launches
- Patent expiries
- Data definitions, limitations and assumptions
- Standard units
- Japanese market data
- Derivation of sales forecasts and pricing trends
- Forecast methodology
- APPENDIX B
- Contributing experts
- Report methodology
- About Datamonitor
- About Datamonitor Healthcare
- About the Disease analysis team
- Disclaimer
- List of Tables
- Table 1: Antihypertensive sales in the seven major markets by class, 2006-07
- Table 2: Sales of antihypertensives across the seven major markets by country, 2007
- Table 3: Sales of the leading branded drugs for hypertension in the seven major markets, 2007
- Table 4: Leading branded drug sales for hypertension in the seven major markets and Rest of World, 2007
- Table 5: Forecast sales growth of hypertension drugs by class in the seven major markets, 2007-17
- Table 6: Forecast sales of antihypertensives in the seven major markets, 2007-2017
- Table 7: Leading angiotensin receptor blockers sales($m) for hypertension in the seven major markets, 2007-2017
- Table 8: Leading angiotensin receptor blockers single pill combinations sales ($m) for hypertension in the seven major markets,2007-2017
- Table 9: Blopress/Atacand: key facts
- Table 10: Sales forecast ($m) for Blopress for hypertension in the seven major markets, 2007-2017
- Table 11: Sales forecast ($m) for Atacand for hypertension in the seven major markets, 2007-2017
- Table 12: Diovan: key facts
- Table 13: Sales forecast ($m) for Diovan for hypertension in the seven major markets, 2007-2017
- Table 14: Sales forecast ($m) for Co-Diovan for hypertension in the seven major markets, 2007-17
- Table 15: Key facts: Cozaar
- Table 16: Sales forecast ($m) for Cozaar for hypertension in the seven major markets, 2007-2017
- Table 17: Sales forecast ($m) for Hyzaar for hypertension in the seven major markets, 2007-2017
- Table 18: Micardis: key facts
- Table 19: Sales forecast ($m) for Micardis for hypertension in the seven major markets, 2007-2017
- Table 20: Benicar: key facts
- Table 21: Sales forecast ($m) for Benicar for hypertension in the seven major markets, 2007-2017
- Table 22: Leading angiotensin converting enzyme inhibitors sales ($m) for hypertension in the 7 MM seven major markets,2007-2017
- Table 23: Leading beta-blockers sales ($m) for hypertension in the seven major markets, 2007-2017
- Table 24: Betaloc/Toprol-XL: key facts
- Table 25: Sales forecast ($m) for Betaloc for hypertension in the seven major markets, 2007-2017
- Table 26: Kredex/Coreg: key facts
- Table 27: Leading calcium-channel blockers sales ($m)for hypertension in the seven major markets, 2007-2017
- Table 28: Norvasc: key facts
- Table 29: Datamonitor' s launch dates for hypertension products in the 5 EU and US, 2008-2017
- Table 30: Patent expiry dates used in forecasting antihypertensive sales in the seven major markets, 2007-2017
- List of Figures
- Figure 1: Antihypertensive market share by class in the seven major markets, 2004-07
- Figure 2: Growth in the antihypertensives market by country, 2004-07
- Figure 3: Antihypertensive sales in the US, 5 EU and Japan, 2004-07
- Figure 4: Overall antihypertensive sales by country, 2006-07
- Figure 5: Key events impacting the hypertension market,2004-08
- Figure 6: Sales of antihypertensives by market type,2007
- Figure 7: Global hypertension sales growth by market segment, 2004-07
- Figure 8: Comparison of leading branded drug growth for hypertension in the seven major markets and Rest of World*, 2006-07
- Figure 9: Forecast sales of antihypertensive drugs by class and value in the seven major markets ($ bn), 2007-2017
- Figure 10: Forecast sales of antihypertensive drugs by class and volume in the seven major markets, 2007-2017
- Figure 11: Market share of antihypertensives by class,2007 and 2017
- Figure 12: Impact of key events on the antihypertensive market, 2007-2017
- Figure 13: Market share of leading brands, 2007 and 2017
- Figure 14: Forecast sales of angiotensin receptor blockers, 2007-2017
- Figure 15: Hypertension-specific sales ($m) forecast for Blopress in the seven major markets, 2007-2017
- Figure 16: Hypertension-specific sales ($m) forecast for Diovan in the seven major markets, 2007-2017
- Figure 17: Hypertension-specific sales ($m) forecast for Cozaar in the seven major markets, 2007-17
- Figure 18: Hypertension-specific sales ($m) forecast for Micardis in the seven major markets, 2007-2017
- Figure 19: Hypertension-specific sales ($m) forecast for Benicar in the seven major markets, 2007-2017
- Figure 20: Forecast sales of angiotensin converting enzyme inhibitors, 2007-17
- Figure 21: Hypertension-specific sales ($m) forecast for Lotrel in the seven major markets, 2007-2017
- Figure 22: Forecast sales of beta blockers, 2007-17
- Figure 23: Hypertension-specific sales ($m) forecast for BETALOC in the seven major markets, 2007-2017
- Figure 24: Hypertension-specific sales ($m) forecast for Kredex in the seven major markets, 2007-2017
- Figure 25: Forecast sales of calcium channel blockers in the seven major markets, 2007-2017
- Figure 26: Hypertension -specific sales ($m) forecast for Norvasc in the US only, 2007-2017
